SM
ADVM

Sabby Management’s Adverum Biotechnologies ADVM Stock Holding History

Sabby Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17
Closed -$102K – 123
2018
Q3 		$102K Buy
+17
New +$955 0.01% 100
2015
Q4 		– Sell
-30
Closed -$247K – 317
2015
Q3 		$247K Buy
+30
New +$3.83K 0.01% 340

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Sabby Management's ADVM Position: Q3 2018 in Review

Sabby Management sold out of Adverum Biotechnologies (ADVM) in Q3 2018, closing a stake of 2,726 shares — an estimated $153K sold.

Sabby Management first reported a position in ADVM in Q3 2014 and held it in 15 quarters. The position peaked at $4.73M in Q3 2015. 101 funds tracked by Wall St. Rank hold ADVM as of Q3 2018.

  • Sabby Management reported no remaining Adverum Biotechnologies position as of Q3 2018 after selling out during the quarter.
  • Sabby Management sold 2,726 Adverum Biotechnologies shares in Q3 2018, an estimated $153K.
  • Sabby Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 15 quarters.
  • Sabby Management's Adverum Biotechnologies position peaked at $4.73M in Q3 2015.
  • 101 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2018.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.